BRCA Carriers Slicing Breast Cancer Odds International Study: Does Surgery Lead to Longevity Leaps?

This session dives into the groundbreaking results of the Phase 3 Patina Trial, showcasing the efficacy of CDK4/6 inhibitors (Palbociclib) in HER2-positive, ER-positive metastatic breast cancer. Presented with key clinical findings, progression-free survival data, and real-world implications, this discussion highlights the role of combination therapies in delaying chemotherapy and improving patient outcomes.

🔍 Key Topics Covered:

Progression-Free Survival (PFS) results
Toxicity and safety profiles
Clinical practice implications
Future regulatory steps
Chapters:
0:00 - Background: HER2+ and ER+ Breast Cancer
0:09 - Why CDK4/6 Inhibitors? Scientific Rationale
0:30 - Overview of the Phase 3 Patina Trial Design
1:06 - Patient Population and Baseline Characteristics
1:30 - Key Results: Progression-Free Survival (PFS)
2:20 - Subgroup Analysis and Secondary Objectives
3:00 - Confirmed Overall Response and Clinical Benefit Rate
3:50 - Overall Survival Data (Immature)
4:15 - Toxicity Profile and Safety Signals
5:10 - Clinical Implications and New Standard of Care
5:45 - Future Steps: FDA and Regulatory Plans
6:40 - Conclusion: Delaying Chemotherapy While Maintaining Quality of Life

👩‍⚕️ Who Should Watch:
Oncologists, healthcare professionals, and researchers interested in metastatic breast cancer advancements.

📈 Subscribe for more updates on cutting-edge cancer research and clinical trial results!

Видео BRCA Carriers Slicing Breast Cancer Odds International Study: Does Surgery Lead to Longevity Leaps? канала OncologyTube